Levodopa - MeSH

Select item 680079801.

The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Year introduced: 1975

Select item 670876582.

levodopa receptor [Supplementary Concept]

Date introduced: July 9, 1994

Select item 670354203.

levodopa methyl ester [Supplementary Concept]

RN given refers to parent cpd(L)-isomer

Date introduced: January 1, 1974

Select item 670092654.

carbidopa, levodopa drug combination [Supplementary Concept]

Date introduced: January 1, 1975

Select item 670051775.

benserazide, levodopa drug combination [Supplementary Concept]

combination of L-Dopa and seryltrihydroxybenzylhydrazine; used in treatment of parkinsonism

Date introduced: January 1, 1973

Select item 675311586.

levodopa-2,6-dimethyl-beta-cyclodextrin [Supplementary Concept]

Date introduced: September 4, 2008

Select item 674543597.

levodopa ethylester [Supplementary Concept]

a highly soluble prodrug of levodopa, may overcome the impaired absorption of regular levodopa, due mainly to a combination of levodopa's poor solubility and delayed gastric emptying

Date introduced: May 15, 2002

Select item 671117158.

levodopa 2,2-dimethylcyclopentyl ester [Supplementary Concept]

structure in first source

Date introduced: May 4, 1998

Select item 671117149.

levodopa cyclopentyl ester [Supplementary Concept]

structure in first source

Date introduced: May 4, 1998

Select item 6711032110.

levodopa cyclohexyl ester [Supplementary Concept]

Date introduced: February 17, 1998